- How—and Why—the Owner of Jameson and Absolut Has Been Aggressively Expanding Its Portfolio of U.S. Alcohol BrandsCraft distilling is still small compared to craft beer, but Pernod Ricard is clearly trying to get ahead of the trend and also hunting for some buzzy growth.
- FDA Approves Sarepta Duchenne Drug in Stunning ReversalIn a surprise, the FDA reversed course and approved Sarepta's Duchenne drug. It's not the first time this has happened—and Sarepta stock soared.
- Meet Stephen Hahn, the New FDA CommissionerThe Senate has confirmed MD Anderson's Stephen Hahn as the next FDA commissioner. Here's what you should know.
- U.S. and China Agree to a 'Phase One' Trade DealSo, for now, there will be no new tariffs on smartphones, toys, and other products made in China.
- Pepsi Is Launching a Cola and Coffee Hybrid DrinkPepsi Café has twice the caffeine of a regular Pepsi.
- Home Depot Says the Opioid Crisis May Drive Theft. But It's ComplicatedRetail giant Home Depot says that the opioid epidemic may be a factor in store thefts—but it's complicated.
- Why Near-Unicorn Zilingo Doesn't Glamorize Valuation or FundraisingThe founder of near-unicorn Zilingo is careful not to harp on how much it has raised in funding and its valuation.
Skip to Content